Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies

  • End date
    Jul 24, 2025
  • participants needed
  • sponsor
    Dana-Farber Cancer Institute
Updated on 24 March 2022
neutrophil count
hepatocellular carcinoma


This research study is studying the Surefire Infusion System ("Surefire") for increasing delivery of chemotherapeutic agents delivered trans-arterially to intermediate stage Hepatocellular Carcinoma ("HCC") (Barcelona Clinic Liver Cancer (BCLC) class B; locally advanced, liver restricted disease patients.

The names of the study interventions involved in this study are:

-Trans-arterial chemoembolization ("TACE") with or without the utilization of Surefire


This research study is a randomized Pilot study, which is the first time investigators are examining use of the Surefire device to improve tumor perfusion. Specifically, this study compares TACE both with or without the use of the Surefire device

Investigators are doing this research to determine if a Surefire Infusion System can improve tumor response to liver-directed intra-arterial chemotherapy compared to a traditional microcatheter.

Surefire is a Food and Drug Administration-approved valve-like device that blocks backflow within the artery but also generates increased pressure in a tumor feeder vessel during infusion. During this study, participants will receive the same medication in the same dose and the same way it would be delivered to the liver as a standard of care procedure, only either through a regular microcatheter (which is the standard of care procedure) or a Surefire Infusion System (which is a modified microcatheter).

Condition Liver Cancer
Treatment doxorubicin, Surefire, Traditional Delivery
Clinical Study IdentifierNCT02853500
SponsorDana-Farber Cancer Institute
Last Modified on24 March 2022


Yes No Not Sure

Inclusion Criteria

Unresectable HCC, defined by imaging criteria or cytohistologic assessment. TACE as a preferred method of treatment is determined by a multidisciplinary Brigham and Women's Hospital / Dana Farber Cancer Institute (BWH/DFCI) Liver Tumor Board
Intermediate stage HCC (BCLC class B), not eligible for curative treatment, but with Child-Pugh A or B. Additionally, tumor cannot involve greater than 50% of the entire liver
Prior systemic chemotherapy is allowable
Age 18-75 years. The pediatrics population is not included as this disease has very low prevalence in that population
Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%, see Appendix A)
Life expectancy of greater than at least 12 months
Participants must have normal organ and marrow function as defined below
leukocytes ≥3,000/mcL
absolute neutrophil count ≥1,500/mcL
platelets ≥60,000/mcL
total bilirubin within normal institutional limits
Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) ≤2.5 × institutional upper limit of normal
creatinine within normal institutional limits or
creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
No previous regional treatment (includes surgery, radiation or liver-directed arterial
or ablative therapy)
Main tumor size > 1 cm
The effects of the study arm on the developing human fetus are unknown, however they are no different than for those in the control group. In addition, because significant radiation will be delivered during the procedure, a positive pregnancy test will exclude patients from the study in addition to excluding them from receiving standard therapy
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

Participants who have had prior local regional therapy including radiation therapy, trans-arterial therapy, or ablative therapy
A hypovascular tumor (defined as a tumor with all its parts less contrast-enhanced than the non-tumorous liver parenchyma on arterial phase computed tomography scans)
Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
Evidence of hepatic decompensation including esophageal or gastric variceal bleeding or hepatic encephalopathy
Severe underlying cardiac or renal diseases
Color Doppler ultrasonography showing portal vein tumor thrombosis with complete main portal vein obstruction without cavernous transformation; or obstructive jaundice
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Human Immunodeficiency Virus (HIV)-positive patients are NOT excluded from the study
Patients who cannot undergo MRI evaluation/examination (eg. pacemaker or other metallic implant)
History of allergic reactions attributed to agents used in study (i.e. doxorubicin, epirubicin, MRI contrast agents or iodinated contrast agents)
Pregnant women are excluded from this study because the chemotherapy utilized within the chemoembolic agent is teratogenic agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemoembolic agent, breastfeeding should be discontinued if the mother is treated with chemoembolic agent. These potential risks may also apply to other agents used in this study as well as from the radiation associated with the angiographic procedure
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note